ArticleDiabetes, obesity & metabolism2021

Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.

Hertzel C Gerstein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.